CZM pre-released a strong set of Q2 20/21 results. Sales outperformance was driven by the faster-than-expected ramp-up of ‘elective’ ophthalmic procedures and the profitability beat was led by a favourable product mix and lower selling expenses amidst the pandemic. Management anticipates an ongoing normalisation of business during the rest of the year and has shared an encouraging guidance for FY20/21.
30 Apr 2021
Solid recovery in Q2 20/21
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Solid recovery in Q2 20/21
CZM pre-released a strong set of Q2 20/21 results. Sales outperformance was driven by the faster-than-expected ramp-up of ‘elective’ ophthalmic procedures and the profitability beat was led by a favourable product mix and lower selling expenses amidst the pandemic. Management anticipates an ongoing normalisation of business during the rest of the year and has shared an encouraging guidance for FY20/21.